Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Cabio Biotech (Wuhan) Revenue

Cabio Biotech (Wuhan) had revenue of 11.01M CNY in the quarter ending March 31, 2026, a decrease of -92.94%. This brings the company's revenue in the last twelve months to 418.18M, down -29.66% year-over-year. In the year 2025, Cabio Biotech (Wuhan) had annual revenue of 563.14M with 1.36% growth.

• Revenue (ttm): 418.18M
• Revenue Growth: -29.66%
• P/S Ratio: 6.62
• Revenue / Employee: 740.15K
• Employees: 574
• Market Cap: 2.77B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	563.14M	7.54M	1.36%
Dec 31, 2024	555.59M	111.79M	25.19%
Dec 31, 2023	443.80M	10.38M	2.39%
Dec 31, 2022	433.42M	82.32M	23.44%
Dec 31, 2021	351.11M	27.65M	8.55%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 10, 2026

Data Sources Report a data error